These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 27435398)

  • 21. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
    Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
    Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
    Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
    Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.
    Thomas MA; Spencer JF; Toth K; Sagartz JE; Phillips NJ; Wold WS
    Mol Ther; 2008 Oct; 16(10):1665-73. PubMed ID: 18665155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity.
    Garofalo M; Iovine B; Kuryk L; Capasso C; Hirvinen M; Vitale A; Yliperttula M; Bevilacqua MA; Cerullo V
    Mol Cancer Ther; 2016 Apr; 15(4):651-60. PubMed ID: 26861248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.
    Cheng PH; Rao XM; Duan X; Li XF; Egger ME; McMasters KM; Zhou HS
    J Mol Med (Berl); 2015 Feb; 93(2):211-23. PubMed ID: 25376708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
    Shashkova EV; Spencer JF; Wold WS; Doronin K
    Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of JNK phosphorylation as a molecular target to enhance adenovirus replication, oncolysis and cancer therapeutic efficacy.
    Wechman SL; Rao XM; Gomez-Gutierrez JG; Zhou HS; McMasters KM
    Cancer Biol Ther; 2018; 19(12):1174-1184. PubMed ID: 30067431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
    Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
    Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
    Thomas MA; Spencer JF; Wold WS
    Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
    Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.